Dr. Buchanan will helm Belharra's research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - ...

Zymeworks (NYSE: ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Chicago-based Meitheal Pharmaceuticals, along with its Chinese parent, was busy in 2024, adding both biosimilar drugs and ...

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...

Research in cancer genetics continues to unravel complex genetic interactions and their implications for cancer development and treatment. Reviews in Cancer ...